Show simple item record

dc.contributor.authorParekh, K
dc.contributor.authorNoghabi, HS
dc.contributor.authorLopez, JA
dc.contributor.authorLi, PCH
dc.date.accessioned2021-06-15T22:26:39Z
dc.date.available2021-06-15T22:26:39Z
dc.date.issued2020
dc.identifier.issn2578-532X
dc.identifier.doi10.20517/cdr.2019.77
dc.identifier.urihttp://hdl.handle.net/10072/405145
dc.description.abstractAims: Triple-negative breast cancer patients are commonly treated with combination chemotherapy. Nonetheless, outcomes remain substandard with relapses being of a frequent occurrence. Among the several mechanisms that result in treatment failure, multidrug resistance, which is mediated by ATP-binding cassette proteins, is the most common. Regardless of the substantial studies conducted on the heterogeneity of cancer types, only a few assays can distinguish the variability in multidrug resistance activity between individual cells. We aim to develop a single-cell assay to study this. Methods: This experiment utilized a microfluidic chip to measure the drug accumulation in single breast cancer cells in order to understand the inhibition of drug efflux properties. Results: Selection of single cells, loading of drugs, and fluorescence measurement for intracellular drug accumulation were all conducted on a microfluidic chip. As a result, measurements of the accumulation of chemotherapeutic drugs (e.g., daunorubicin and paclitaxel) in single cells in the presence and absence of cyclosporine A were conducted. Parameters such as initial drug accumulation, signal saturation time, and fold-increase of drug with and without the presence cyclosporine A were also tested. Conclusion: The results display that drug accumulation in a single-cell greatly enhanced over its same-cell control because of inhibition by cyclosporine A. Furthermore, this experiment may provide a platform for future liquid biopsy studies to characterize the multidrug resistance activity at a single-cell level.
dc.description.peerreviewedYes
dc.publisherOAE Publishing Inc.
dc.relation.ispartofpagefrom613
dc.relation.ispartofpageto622
dc.relation.ispartofissue3
dc.relation.ispartofjournalCancer Drug Resistance
dc.relation.ispartofvolume3
dc.subject.fieldofresearchBiomedical engineering
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode4003
dc.subject.fieldofresearchcode3211
dc.titleMicrofluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationParekh, K; Noghabi, HS; Lopez, JA; Li, PCH, Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells, Cancer Drug Resistance, 2020, 3 (3), pp. 613-622
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2021-06-15T21:57:06Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorLopez Ramirez, Alejandro


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record